Testing a new imaging dye for lung cancer
Part of Cancer clinical trials.
This study tests a new imaging dye (called a probe) that targets a specific change in lung cancer cells (EGFR mutation). The PET/CT scan uses this dye to see if the tumor can be clearly seen, which might help doctors plan better treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed lung cancer diagnosis with a tumor that can be measured on scans.
- You need to be able to have a PET/CT scan and follow the imaging instructions.
- Your age must be between 18 and 75 years.
- You should be in good physical condition (able to manage daily activities on your own).
- You must be willing to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that helps find cancer cells that have come back. It is given as an injection and then a scan is done to see if it helps doctors locate the cancer.
This study tests a new imaging agent that helps PET scans show cancer more clearly. It may help doctors see where cancer is in your body and plan your treatment better.
This trial tests a new imaging agent that may help doctors see tumors more clearly during a PET scan. It is for people with certain types of cancer who are willing to have a biopsy of their tumor.
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This trial uses a new radioactive tracer that attaches to a protein found on many solid tumors, allowing doctors to see tumors on a PET scan. It may help improve how tumors are detected and monitored.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.